semaglutide and prostate cancer ESMO 2023: Enzalutamide 177Lu-PSMA-617 in Poor-Risk Metastatic Castration-Resistant (mCRPC), a Randomized, Phase 2 Trial Prostate Cancer Treatment (PDQ®) -
Pay in 4 interest-free payments of $5.99 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 23 - Nov 28



























